Advisers to the U.S. health regulator on Thursday voted in favor of recommending a full approval for Pfizer's COVID-19 pill Paxlovid in adults at high risk of progression to severe disease.
Paxlovid, Pfizer's anti-viral medication to treat the coronavirus disease , is displayed in this picture illustration taken October 7, 2022.
Wolfgang Rattay/IllustrationMarch 16 - Advisers to the U.S. health regulator on Thursday voted in favor of recommending a full approval for Pfizer'sThe Food and Drug Administration's panel of external advisers voted 16-to-1 in favor of the drug's benefits outweighing its risk for some adults with mild-to-moderate COVID-19.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
No clear association between Paxlovid and COVID-19 rebound, FDA saysAn FDA analysis did not find a clear association between the COVID-19 antiviral drug Paxlovid and illness rebound, the FDA said in a new report.
Weiterlesen »
Paxlovid not linked to COVID rebound, FDA saysClinical trial data has concluded that there is no clear association with a COVID-19 rebound.
Weiterlesen »
Paxlovid not linked to COVID rebound, FDA saysThe FDA gave the COVID-19 anti-viral emergency use authorization in 2021 for treating mild to moderate illness in high-risk adults.
Weiterlesen »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisersare backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness
Weiterlesen »
COVID-19 pill Paxlovid moves closer to full FDA approvalPfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers, clearing the way for its full approval by the FDA. The medication has been used by millions of Americans since it was granted emergency use authorization in 2021.
Weiterlesen »
COVID-19 pill Paxlovid moves closer to full FDA approvalU.S. health advisors are backing the continued use of Pfizer’s COVID-19 pill Paxlovid, saying it remains an important option for adults at high risk of severe illness.
Weiterlesen »